Inscription Capital LLC Invests $335,000 in Novo Nordisk A/S (NYSE:NVO)

Inscription Capital LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 4,831 shares of the company's stock, valued at approximately $335,000.

Other hedge funds have also modified their holdings of the company. Strategic Investment Solutions Inc. IL grew its position in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares during the last quarter. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $29,000. Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $33,000. CX Institutional acquired a new position in shares of Novo Nordisk A/S during the 1st quarter worth $36,000. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $39,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO stock traded down $0.32 during trading hours on Thursday, hitting $74.03. The company's stock had a trading volume of 5,456,477 shares, compared to its average volume of 7,077,971. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The business has a fifty day moving average of $67.98 and a 200-day moving average of $79.17. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The stock has a market cap of $332.19 billion, a price-to-earnings ratio of 21.90, a P/E/G ratio of 1.33 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion for the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on NVO shares. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating on the stock. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of "Hold" and a consensus price target of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.